Waban, MA – According to filings with the U.S. Securities and Exchange Commission, Thermalin Inc. is raising $23 Million in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Richard Berenson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Thermalin Inc.

Thermalin is engineering new forms of insulin that will lower the burden of insulin use, increase patient adoption of and adherence to insulin therapy, improve patient lives and outcomes, and lower the cost of caring for people with Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D). Founded in 2010 based on pioneering work by Dr. Michael Weiss on the structure and function of insulin analogues, Thermalin is overcoming the limitations of existing insulin products by re-engineering the insulin molecule to be more stable and to act more selectively. Thermalin’s formulations of these new molecules enable new delivery devices and systems that will transform lives.

To learn more about Thermalin Inc., visit http://thermalin.com/

Contact:
Richard Berenson, Chief Executive Officer
617-695-0523
rick@thermalin.com
https://www.linkedin.com/in/richardberenson/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved